// App-Quantinova.ai

3247 : DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Researchers

Presenter

  • Robert M. Rifkin

Principal Investigators

  • Sebastian Grosicki

  • Kihyun Kim

  • Francesco Di Raimondo

  • Meletios A Dimopoulos

  • Katja Weisel

  • Bertrand Arnulf

  • Roman Hajek

  • Vania T. M. Hungria

  • Andrew Spencer

  • Randy Davis

  • Antonio Riccio

  • Chanbin Kim

  • Jodie Wilkes

  • Ruth Rutledge

  • Mala Talekar

  • Brandon E. Kremer

  • Ira Gupta

  • Maria-Victoria Mateos

Medical Centers

  • Rocky Mountain Cancer Center, Denver, CO

  • Royal Marsden Hospital, Surrey, United Kingdom

  • Faculty of Public Health, Medical University of Silesia, Katowice, Poland

  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy

  • School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

  • Hematology/Oncology, Hopital Saint Louis, Paris, France

  • Dept. of Hematology/Oncology, Charles University Hospital, Pilsen, Czech Republic,

  • Sao Germano Clinic, Sao Paulo, Brazil

  • Department of Clinical Haematology, The Alfred Hospital and Monash University, Melbourne, Australia

  • GlaxoSmithKline, Research Triangle Park, NC

  • GlaxoSmithKline, Waltham, MA

  • GlaxoSmithKline, Bethesda, MD

  • GlaxoSmithKline, Stevenage, United Kingdom.

  • GlaxoSmithKline, Lansdale, PA

  • GlaxoSmithKline, Philadelphia, PA.

  • Cancer Research Center-IBMCC (USAL-CSIC), University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain

Locations

  • United States

  • United Kingdom

  • Poland

  • Republic of South Korea

  • Italy

  • Greece

  • Germany

  • France

  • Czech Republic

  • Brazil

  • Australia

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • GSK2857916

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • daratumumab Intravenous

  • Bortezomib

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Open Label

  • Multiple Arm

  • Multinational

  • Multicenteric

Phase

  • III

Study Id's

  • NCT04246047

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved